Experience the Quality With Free AOCNP Exam Questions That Helps Candidates Pass

Body image concerns are common after breast surgery and can impair intimacy, mood, and social functioning. Evidence-based care begins with validation and structured assessment (screen for depression/anxiety, sexual health, relationship stress). Early, practical supports—professional prosthesis fitting, specialty bras, and education on scar care—can restore confidence quickly. Timely referral to a reconstructive surgeon for counseling on options (immediate/delayed, implant vs autologous) empowers choice. Psycho-oncology services and peer support groups address grief, identity, and coping; skills such as graded exposure, mindfulness, and communication coaching improve self-efficacy. Simple reassurance (Option A) risks prolonging suffering. Narrowing visits to disease surveillance (Option C) overlooks holistic survivorship needs. Benzodiazepines (Option D) without a plan may worsen avoidance and do not address core issues. The APRN should document goals, provide curated resources (appearance centers, survivorship programs), include partners when desired, and follow up to reassess adjustment, tailoring interventions as recovery progresses.

Responsible opioid stewardship integrates regulatory compliance with patient-centered pain control. Reviewing the Prescription Drug Monitoring Program (PDMP) at initiation and periodically identifies undisclosed prescriptions and risk patterns. Baseline risk assessment (validated tools plus history), informed consent/treatment agreements, explicit functional goals, and naloxone co-prescribing constitute best practice. Urine drug testing and pill counts are used judiciously based on risk level and clinical context. Blanket prohibitions on telehealth (Option C) or rigid monthly visits for all (Option D) create barriers without improving safety; instead, use risk-stratified follow-up (telehealth + labs for stable patients). Skipping PDMP checks (Option A) contravenes safety and many state rules. APRNs should document dosing (MME calculations), taper plans when benefits do not outweigh risks, non-opioid multimodal strategies, and coordination with palliative care/behavioral health. Consistent policies, clinician education, and audit/feedback support adherence and equitable application across patient populations.

Symptomatic or ECG-significant hyperkalemia is life-threatening. The FIRST step is myocardial stabilization with IV calcium (e.g., calcium gluconate 1–2 g), which counteracts membrane excitability within minutes but does not lower serum potassium. Immediately follow with intracellular shifting strategies—regular insulin (e.g., 10 units IV) plus dextrose to prevent hypoglycemia; consider nebulized albuterol and/or sodium bicarbonate if acidosis. Begin or continue aggressive isotonic IV fluids to promote renal excretion and avoid potassium-containing solutions. Arrange definitive potassium removal with loop diuretics if euvolemic and responsive kidneys, potassium binders as adjuncts, and early nephrology consult for dialysis if refractory or in renal failure. Sodium polystyrene alone (Option A) has delayed onset and questionable efficacy for emergencies. Allopurinol (Option C) treats uric acid formation, not acute hyperkalemia. Stopping fluids (Option D) worsens renal clearance and TLS risk. APRNs must implement a TLS pathway: frequent labs, cardiac monitoring, rasburicase for hyperuricemia when appropriate, and clear thresholds for dialysis.

Respect for autonomy requires verifying that refusals are informed and voluntary. A structured capacity assessment confirms the patient can understand relevant information, appreciate consequences for personal circumstances, reason about options, and communicate a stable choice. The APRN should optimize contributors that can impair capacity (uncontrolled pain, delirium, severe depression, hypoxia), provide clear information using teach-back, and explore values/goals to ensure alignment. If capacity is intact, an informed refusal is ethically and legally valid; document the discussion, risks/benefits, and availability of supportive/palliative care. Treating against will (Option A) or seeking legal compulsion (Option C) without evidence of incapacity violates ethics and law. Deferring to family (Option D) is appropriate only when the patient lacks capacity and a surrogate is designated. Offer ongoing relationship-centered support; preferences may evolve, and patients should know they can revisit decisions anytime. This approach maintains trust, reduces conflict, and centers care on what matters most to the patient.

Acute laryngopharyngeal dysesthesia is a characteristic, non-IgE phenomenon with oxaliplatin—sensations of throat tightening or dyspnea often triggered by cold exposure, usually early in treatment. It is frightening but not true bronchospasm or anaphylaxis. Immediate steps are to stop or slow the infusion, keep the patient warm, and provide warm liquids; symptoms typically abate quickly. For subsequent cycles, avoid cold beverages/exposure for 48–72 hours, and consider prolonging infusion duration to reduce peak levels. True hypersensitivity reactions to oxaliplatin occur later after multiple cycles and present with flushing, hypotension, wheeze, or rash—those require antihistamines, steroids, and potentially desensitization protocols. Routine epinephrine (Option A) is unnecessary absent anaphylaxis. High-dose steroids without addressing cold trigger (Option C) adds little benefit. Switching agents (Option D) sacrifices efficacy without cause. APRNs should educate proactively on cold sensitivity, counsel on neuropathy prevention behaviors, and document the event and planned modifications for team consistency.